DISCLAIMER: THIS PAGE IS INTENDED FOR HEALTHCARE PROFESSIONALS IN France ONLY.

Information about the NuvaxovidTM ▼ COVID-19 Vaccine (recombinant, adjuvanted) (also known as NVX-CoV2373)

NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted) has been granted full marketing authorisation by the EMA for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older in accordance with official recommendations. Nuvaxovid can be administered as booster dose approximately 6 months after the second dose in individuals 18 years of age and older.

Report an Adverse Event (AE)

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system of France.

Agence nationale de sécurité du médicament et des produits de santé (ANSM) et réseau des Centres Régionaux de Pharmacovigilance
Site internet: www.signalement-sante.gouv.fr

Contact Us

Tel: +33 1 82 88 32 29
09:00 - 17:00
Monday - Friday